Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Interest & Investment Income (2019 - 2025)

Harmony Biosciences Holdings' Interest & Investment Income history spans 7 years, with the latest figure at $5.9 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 30.76% year-over-year to $5.9 million; the TTM value through Dec 2025 reached $21.9 million, up 18.24%, while the annual FY2025 figure was $21.9 million, 18.24% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $5.9 million at Harmony Biosciences Holdings, up from $5.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $20.0 million in Q4 2021 and bottomed at -$7.2 million in Q2 2021.
  • The 5-year median for Interest & Investment Income is $4.3 million (2023), against an average of $2.3 million.
  • The largest annual shift saw Interest & Investment Income skyrocketed 351.15% in 2021 before it tumbled 73.07% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $20.0 million in 2021, then fell by 23.97% to $15.2 million in 2022, then crashed by 73.07% to $4.1 million in 2023, then increased by 9.3% to $4.5 million in 2024, then surged by 30.76% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Interest & Investment Income are $5.9 million (Q4 2025), $5.7 million (Q3 2025), and $5.3 million (Q2 2025).